Clinical trials: Clostridoides Difficile Associated Disease
Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence
Secondary Prevention of Clostridioides Difficile Using Vancomycin
Re-exposure to systemic antibiotics (i.e., antibiotics absorbed into the bloodstream) is common after a Clostridioides difficile infection (CDI) and is the strongest risk factor for a recurrent episode.
- Conditions
- Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Clostridoides Difficile Associated Disease
- Trial name
- SPORES-V (NCT06979609)
- Testing
- Oral Vancomycin Prophylaxis
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Clostridoides Difficile Associated Disease
To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults
An antibody is a substance your body makes to fight off infection. This study will explore the safety and antibody response of a vaccine to prevent severe diarrhea caused by a germ called Clostridoides difficile (C. diff).
- Trial name
- NCT05805826
- Testing
- C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2.
- Where
- 23 sites in United States
- Volunteers
- 936 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridoides Difficile Associated Disease
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
The purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older.
- Trial name
- BEETHOVEN (NCT07282665)
- Testing
- C.difficile vaccine
- Where
- 186 sites in United States, Argentina and 2 more
- Volunteers
- 32,500 people, healthy volunteers welcome
- Sponsor
- Pfizer